ScholarIQanswers from OpenAlex & ORCID
Richard G. Langley
ResearcherPublications, citations & collaboration network
Richard G. Langley is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Richard G. Langley have?
ScholarIQindexed works
Richard G. Langley has 422 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Richard G. Langley have?
ScholarIQcitation count
Richard G. Langley has 27,270 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Richard G. Langley?
ScholarIQh-index
Richard G. Langley has an h-index of 76 in OpenAlex.
What is the i10-index of Richard G. Langley?
ScholarIQi10-index
Richard G. Langley has an i10-index of 187 in OpenAlex.
What is the ORCID of Richard G. Langley?
ScholarIQorcid
The ORCID for Richard G. Langley is on the source record.
What is the OpenAlex record for Richard G. Langley?
ScholarIQopenalex
The OpenAlex for Richard G. Langley is on the source record.
What are the most-cited papers on Richard G. Langley?
ScholarIQmost cited works
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce Strober, Martin Kaul, Yihua Gu, Martin M. Okun, Kim Papp
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, Kristian Reich, David A. Amato, Susan Ball, Daniel Braun, Gregory S. Cameron, J. Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris, Craig L. Leonardi
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula
Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
Mark Lebwohl, H. Bachelez, Jonathan Barker, Giampiero Girolomoni, Arthur Kavanaugh, Richard G. Langley, C. Paul, L. Puig, Kristian Reich, P.C.M. van de Kerkhof